Mantovani, A, Byrne, CD, Zheng, MH, Targher, G, Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 30 (2020), 1236–1248.
Apicella, M, Campopiano, MC, Mantuano, M, Mazoni, L, Coppelli, A, Del Prato, S, COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 8 (2020), 782–792.
Zhu, Z, Zeng, Q, Liu, Q, Wen, J, Chen, G, Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-19: a systematic review and network meta-analysis. JAMA Netw Open, 5, 2022, e2244652.
Scheen, AJ, Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Khunti, K, Ruan, Y, Davies, J, et al. Association between SGLT2 inhibitor treatment and diabetic ketoacidosis and mortality in people with type 2 diabetes admitted to hospital with COVID-19. Diabetes Care 45 (2022), 2838–2843.
Khedr, A, Hennawi, HA, Khan, MK, et al. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports. World J Clin Cases 11 (2023), 5700–5709.
Scheen, AJ, SGLT2 inhibition during the COVID-19 epidemic: friend or foe?. Diabetes Metab 46 (2020), 343–344.
Kosiborod, MN, Windsor, SL, Vardeny, O, et al. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial. Lancet Diabetes Endocrinol, 2024 published online Sept 6. https://doi.org/10.1016/S2213-8587(24)00218-3.
Vale, C, Godolphin, PJ, Fisher, D, et al. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials. Lancet Diabetes Endocrinol, 2024 published online Sept 6. https://doi.org/10.1016/S2213-8587(24)00219-5.
Matthews, J, Herat, L, Schlaich, MP, Matthews, V, The impact of SGLT2 inhibitors in the heart and kidneys regardless of diabetes status. Int J Mol Sci, 24, 2023, 14243.
Permana, H, Audi Yanto, T, Ivan Hariyanto, T, Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract, 195, 2023, 110205.
ElSayed, NA, Aleppo, G, Aroda, VR, et al. 16. Diabetes care in the hospital: standards of care in diabetes—2023. Diabetes Care 46:suppl 1 (2023), S267–S278.
